Previous Close | 2.1100 |
Open | 2.1900 |
Bid | 1.3000 x 1100 |
Ask | 1.3700 x 1100 |
Day's Range | 2.0301 - 2.4099 |
52 Week Range | 0.7700 - 3.7900 |
Volume | |
Avg. Volume | 3,014,126 |
Market Cap | 154.495M |
Beta (5Y Monthly) | 1.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5900 |
Earnings Date | Mar 19, 2024 - Mar 20, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for RGLS
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Pa